Mild hyperparathyroidism: A novel surgically correctable feature of primary aldosteronism

Journal of Hypertension

Volumn 30, Issue 2, 2012, Pages 390-395

  Maniero, Carmela ^a   Fassina, Ambrogio ^b   Seccia, Teresa M ^a   Toniato, Antonio ^c   Iacobone, Maurizio ^c   Plebani, Mario ^a   De Caro, Raffaele ^c   Calò, Lorenzo A ^a   Pessina, Achille C ^a   Rossi, Gian P ^a  

^a Department of Surgery ^*  (Italy)

^b Section of Cytopathology   (Italy)

^c UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

adrenal gland; aldosterone; calcium; parathormone; parathyroids; primary aldosteronism; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALDOSTERONE; CALCITRIOL; CALCIUM ION; DEOXYPYRIDINOLINE; MAGNESIUM ION; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR 1; PHOSPHORUS; POTASSIUM ION; PROTEIN;

ADRENAL CORTEX ADENOMA; ADRENALECTOMY; ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; URINARY EXCRETION; VITAMIN BLOOD LEVEL;

EID: 84855849111     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834f0451     Document Type: Article

References (24)

1. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293-2300. (Pubitemid 44873058)
2. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921-1926. (Pubitemid 351778191)
3. Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro Hypertension 2007; 50:447-453.
4. Gomez-Sanchez CE, Rossi GP, Fallo F, Mannelli M. Progress in primary aldosteronism: present challenges and perspectives. Horm Metab Res 2010; 42:374-381.
5. Rosenberg J, Pines M, Hurwitz S. Response of adrenal cells to parathyroid hormone stimulation. J Endocrinol 1987; 112:431-437. (Pubitemid 17020880)
6. Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metab 2001; 280:E209-E213.
7. Hanley NA, Wester RM, Carr BR, Rainey WE. Parathyroid hormone and parathyroid hormone-related peptide stimulate aldosterone production in the human adrenocortical cell line, NCI-H295. Endocrine J 1993; 1:447-450. (Pubitemid 2021559)
8. Isales CM, Barrett PQ, Brines M, Bollag W, Rasmussen H. Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology 1991; 129:489-495.
9. Rizk-Rabin M, Assie G, Rene-Corail F, Perlemoine K, Hamzaoui H, Tissier F, et al. Differential expression of parathyroid hormone-related protein in adrenocortical tumors: autocrine/paracrine effects on the growth and signaling pathways in H295R cells. Cancer Epidemiol Biomarkers Prev 2008; 17:2275-2285.
10. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005; 111:871-878. (Pubitemid 40279888)
11. Maniero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR, et al. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension 2011; 58:341-346.
12. Rossi GP; Medscape. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol 2011; 7:485-495.
13. Fassbender WJ, Godde M, Brandenburg VM, Usadel KH, Stumpf UC. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes. Adv Med Sci 2009; 54: 1-6.
14. Broadus AE. Nephrogenous cyclic AMP as a parathyroid function test. Nephron 1979; 23:136-141. (Pubitemid 9138145)
15. Lenzini L, Seccia TM, Aldighieri E, Belloni AS, Bernante P, Giuliani L, et al. Heterogeneity of aldosterone-producing adenomas revealed by a whole transcriptome analysis. Hypertension 2007; 50:1106-1113. (Pubitemid 350172933)
16. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001; 81:239-297. (Pubitemid 32096177)
17. Conn JW. Presidential address I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45:3-17.
18. Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens 1995; 8:884-893.
19. Zia AA, Kamalov G, Newman KP, McGee JE, Bhattacharya SK, Ahokas RA, et al. From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation. Hypertens Res 2010; 33:1091-1101.
20. Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol 2010; 5 (Suppl 1):S23-30.
21. Lee M, Partridge NC. Parathyroid hormone signaling in bone and kidney. Curr Opin Nephrol Hypertens 2009; 18:298-302.
22. Safer JD, Ray S, Holick MF. A topical parathyroid hormone/parathyroid hormone-related peptide receptor antagonist stimulates hair growth in mice. Endocrinology 2007; 148:1167-1170.
23. Fuentes J, Guerreiro PM, Modesto T, Rotllant J, Canario AV, Power DM. A PTH/PTHrP receptor antagonist blocks the hypercalcemic response to estradiol-17beta. Am J Physiol Regul Integr Comp Physiol 2007; 293:R956-960. (Pubitemid 47205084)
24. Rossi GP. Hyperparathyroidism, arterial hypertension and aortic stiffness: a possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage? Hypertens Res 2011; 34:286-288.